Drug Profile
OM 163
Latest Information Update: 08 Oct 2020
Price :
$50
*
At a glance
- Originator OM Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 30 Sep 2020 OM Pharma has been acquired by Optimus Holding
- 14 Dec 2001 Discontinued-Preclinical for Colorectal cancer in Switzerland (Unknown route)